@aurawellaesthetics: The next generation of weight loss medicine is officially in clinical trials. 🧪 It’s called Retatrutide, and it’s a "triple agonist." ​Think of it as the evolution of metabolic health: 👉 Semaglutide targets 1 hormone receptor. 👉 Tirzepatide targets 2 hormone receptors. 👉 Retatrutide targets 3 hormone receptors (GLP-1, GIP, + Glucagon). ​By adding that third receptor, it doesn't just lower appetite—it actually helps the body burn more energy and targets liver fat. ​💡 Why is this a big deal? In Phase 3 clinical trials, Retatrutide has shown unprecedented average weight loss percentages, pushing the boundaries of what metabolic medication can achieve. It’s also showing massive promise in treating Non-Alcoholic Fatty Liver Disease (NAFLD). ​Disclaimer: Retatrutide is currently an investigational drug undergoing clinical trials and is not yet FDA-approved for public prescription. Always consult a healthcare provider for current weight management options. ​Drop your questions about the future of metabolic science below! 👇 #TikTokCreatorSearchInsightsIncentive #peptide #ratatouille #glp1 #education

Aura Wellness and Aesthetics

Open In TikTok:

Region: US

Saturday 20 June 2026 02:27:36 GMT